Literature DB >> 18213713

Neural cell adhesion molecule (NCAM) isoform expression is associated with neuroblastoma differentiation status.

Cynthia Winter1, Bruce Pawel, Eric Seiser, Huaqing Zhao, Eric Raabe, Qun Wang, Alex R Judkins, Edward Attiyeh, John M Maris.   

Abstract

BACKGROUND: NCAM is a member of the immunoglobulin superfamily of cell adhesion molecules. While highly expressed on neuroblastoma cells, the relative contribution of the three major NCAM isoforms (120, 140, and 180 kDa) to neuroblastoma biology has not been investigated.
METHODS: NCAM protein expression was measured in a neuroblastic tumor tissue microarray (N = 185) by immunohistochemistry. Relative expression of NCAM mRNA isoforms was measured in a panel of 24 human neuroblastomas and compared to fetal and adult human brain using real-time quantitative PCR and Western blot analysis. Associations with clinical and tumor biological co-variates were performed.
RESULTS: NCAM protein was detected on all neuroblastic tumors and was highly expressed in all but 7/167 cases. The mRNA species predicted to encode the 120 kDa protein species was the most abundant isoform in adult brain, ganglioneuromas and ganglioneuroblastomas (P = 0.0007), but the mRNA predicted to encode the 180 kDa species was predominant in neuroblastomas (P = 0.043). Microdissected ganglion and neuroblast cells from human primary tumors confirmed these findings.
CONCLUSION: Ganglioneuromas and ganglioneuroblastomas express the adhesive 120 kDa NCAM isoform, while neuroblastomas preferentially express the 180 kDa isoform classically involved in cell motility. These data suggest a mechanism for the enhanced metastatic potential of undifferentiated neuroblastomas. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18213713     DOI: 10.1002/pbc.21475

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  21 in total

1.  Expression and localization of neural cell adhesion molecule and polysialic acid during chick corneal development.

Authors:  Xiuli Mao; Tyler Schwend; Gary W Conrad
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-03-09       Impact factor: 4.799

2.  Claudin-6 is a nonspecific marker for malignant rhabdoid and other pediatric tumors.

Authors:  Lisa M Sullivan; Theresa Yankovich; Paul Le; Daniel Martinez; Mariarita Santi; Jaclyn A Biegel; Bruce R Pawel; Alexander R Judkins
Journal:  Am J Surg Pathol       Date:  2012-01       Impact factor: 6.394

3.  p16INK4A and p14ARF tumor suppressor pathways are deregulated in malignant rhabdoid tumors.

Authors:  Sriram Venneti; Paul Le; Daniel Martinez; Katherine W Eaton; Nikhil Shyam; Kelly L Jordan-Sciutto; Bruce Pawel; Jaclyn A Biegel; Alexander R Judkins
Journal:  J Neuropathol Exp Neurol       Date:  2011-07       Impact factor: 3.685

4.  Serine catabolism regulates mitochondrial redox control during hypoxia.

Authors:  Jiangbin Ye; Jing Fan; Sriram Venneti; Ying-Wooi Wan; Bruce R Pawel; Ji Zhang; Lydia W S Finley; Chao Lu; Tullia Lindsten; Justin R Cross; Guoliang Qing; Zhandong Liu; M Celeste Simon; Joshua D Rabinowitz; Craig B Thompson
Journal:  Cancer Discov       Date:  2014-09-03       Impact factor: 39.397

5.  Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.

Authors:  Andrew C Wood; John M Maris; Richard Gorlick; E Anders Kolb; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Raushan T Kurmasheva; Kathleen Whiteman; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-06-24       Impact factor: 3.167

6.  Characterization of basigin isoforms and the inhibitory function of basigin-3 in human hepatocellular carcinoma proliferation and invasion.

Authors:  Cheng-Gong Liao; Ling-Min Kong; Fei Song; Jin-Liang Xing; Long-Xin Wang; Zhi-Jian Sun; Hao Tang; Hui Yao; Yang Zhang; Li Wang; Yu Wang; Xiang-Min Yang; Yu Li; Zhi-Nan Chen
Journal:  Mol Cell Biol       Date:  2011-05-02       Impact factor: 4.272

7.  MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.

Authors:  Alberto Delaidelli; Gian Luca Negri; Asad Jan; Brandon Jansonius; Amal El-Naggar; Jonathan K M Lim; Debjit Khan; Htoo Zarni Oo; Christopher J Carnie; Marc Remke; John M Maris; Gabriel Leprivier; Poul H Sorensen
Journal:  Cell Death Differ       Date:  2017-06-02       Impact factor: 15.828

Review 8.  More than the genes, the tumor microenvironment in neuroblastoma.

Authors:  Lucia Borriello; Robert C Seeger; Shahab Asgharzadeh; Yves A DeClerck
Journal:  Cancer Lett       Date:  2015-11-17       Impact factor: 8.679

9.  Universal expression of cell adhesion molecule NCAM in neuroblastoma in contrast to L1: implications for different roles in tumor biology of neuroblastoma?

Authors:  Robin Wachowiak; Tamina Rawnaq; Roman Metzger; Alexander Quaas; Henning Fiegel; Nils Kähler; Udo Rolle; Jakob R Izbicki; Jussuf Kaifi; Holger Till
Journal:  Pediatr Surg Int       Date:  2008-12       Impact factor: 1.827

10.  Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.

Authors:  Brian J Lestini; Kelly C Goldsmith; Mark N Fluchel; Xueyuan Liu; Niel L Chen; Bella Goyal; Bruce R Pawel; Michael D Hogarty
Journal:  Cancer Biol Ther       Date:  2009-08-08       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.